 | | Vol. 8.30 – 4 August, 2020 |
| |
|
|
| Scientists compiled an unbiased atlas of human colonic CD8+ T cells in health and ulcerative colitis using single-cell transcriptomics with T-cell receptor repertoire analysis and mass cytometry.
[Nature Medicine] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers present a global map of cysteines in primary human T cells that are susceptible to covalent modification by electrophilic small molecules.
[Cell] |
|
|
|
| Unbiased bioinformatics analysis identified that inducible costimulatory molecule (ICOS)+ folliular helper T cells and other ICOS+ populations, including peripheral helper T cells, were highly sensitive to costimulation blockade.
[Nature Immunology] |
|
|
|
| M1 and M2 macrophage viability and activation were mainly found to be unaffected by few‐layer graphene and MoS2 at doses up to 50 µg mL−1.
[Small] |
|
|
|
| Activated signaling pathways and cytokine production were evaluated in a panel of human biliary tract cancer (BTC) cell lines. Human peripheral blood mononuclear cells were cultured with BTC supernatants, with and without cytokine neutralising antibodies, and analysed by flow cytometry or immunoblot.
[British Journal of Cancer] |
|
|
|
| Investigators explored the efficacy of prophylactic DLI following CTLA4Ig, compared to conventional DLI, in patients with advanced hematological malignancies receiving PTCy-based haploidentical transplantation.
[Bone Marrow Transplantation] |
|
|
|
| Scientists tested ferratin heavy (FeH) and light (FeL) in bone marrow and sera in patients with macrophage activation syndrome, the pro-inflammatory effects of ferritin, FeL, and FeH on macrophages; and the ability of FeH-stimulated macrophages to stimulate the proliferation of peripheral blood mononuclear cells.
[Scientific Reports] |
|
|
|
| The authors compared the inflammatory phenotype of monocytes from Crohn’s disease patients, who responded or non-responded to infliximab. Under basal conditions, the mRNA for the cytokines TNFα, IL-23, IL-1β and the chemokines CXCL8/IL-8, CCL5/RANTES and CCL2/MCP-1 was up-regulated in monocytes from non-responders than responders.
[Scientific Reports] |
|
|
|
| Researchers showed that LW-213 dose-dependently inhibited human cutaneous T-cell lymphoma cell lines with IC50 values of around 10 μM, meanwhile it potently inhibited primary leukemia cells derived from peripheral blood of T-cell lymphoma patients.
[Acta Pharmacologica Sinica] |
|
|
|
| Researchers investigated the role of soluble T-cell immunoglobulin domain and mucin domain-containing molecule-3 in inhibition of release of inflammatory mediators.
[Cell Death Discovery] |
|  |
|
|
|
| The authors review the impact of CD39 expression and ectonucleotidase activity on immunity with a focus on the setting of oncology.
[Nature Reviews Immunology] |
|
|
|
| Investigators highlight recent strategies to improve chimeric antigen therapy (CAR)-T cell therapy by engineering the CAR protein, T cells, and the interaction between T cells and other components in the tumor microenvironment.
[Cancer Cell] |
|
|
|
| Renal cell carcinoma is considered to be an immunogenic tumor but is known to mediate immune dysfunction in large part by eliciting the infiltration of immune-inhibitory cells, such as regulatory T cells and myeloid-derived suppressor cells, into the tumor microenvironment.
[Nature Reviews Nephrology] |
|
|
|
|
| Genmab A/S announced that the European Myeloma Network in collaboration with Janssen Research & Development, LLC reported positive results from the Phase III APOLLO study of the subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone (Pd) versus Pd alone as treatment for patients with relapsed or refractory multiple myeloma who have previously been treated with lenalidomide and a proteasome inhibitor.
[Genmab A/S] |
|
|
|
| MorphoSys AG and Incyte announced that the FDA has approved Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
[MorphoSys AG] |
|
|
|
| Twitter has suspended the account of MeTooSTEM founder BethAnn McLaughlin after allegations emerged that the former Vanderbilt University neuroscientist fabricated the Twitter account of an apparently nonexistent female Native American anthropologist at Arizona State University who had claimed to be an anonymous victim of sexual harassment by a Harvard professor.
[ScienceInsider] |
|
|
|
|
| September 22 – September 25
Martinsried, Germany |
|
|
|
|
|
| | Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| | The Francis Crick Institute – London, United Kingdom |
|
|
|
| | University of Dundee – Dundee, United Kingdom |
|
|
|
| | The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
